Federated Hermes Inc. Has $100.03 Million Holdings in Merus (NASDAQ:MRUS)

Federated Hermes Inc. lifted its holdings in shares of Merus (NASDAQ:MRUS) by 26.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 3,637,309 shares of the biotechnology company’s stock after acquiring an additional 751,609 shares during the quarter. Federated Hermes Inc. owned approximately 0.06% of Merus worth $100,026,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. BluePath Capital Management LLC bought a new position in Merus during the third quarter worth $33,000. China Universal Asset Management Co. Ltd. raised its stake in Merus by 142.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,477 shares of the biotechnology company’s stock worth $35,000 after buying an additional 867 shares during the last quarter. BNP Paribas Arbitrage SA raised its stake in Merus by 107.4% during the second quarter. BNP Paribas Arbitrage SA now owns 1,811 shares of the biotechnology company’s stock worth $41,000 after buying an additional 938 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Merus by 871.4% during the second quarter. JPMorgan Chase & Co. now owns 1,564 shares of the biotechnology company’s stock worth $41,000 after buying an additional 1,403 shares during the last quarter. Finally, Deutsche Bank AG bought a new position in Merus during the fourth quarter worth $45,000. Institutional investors and hedge funds own 96.14% of the company’s stock.

Analysts Set New Price Targets

MRUS has been the subject of a number of analyst reports. StockNews.com downgraded shares of Merus from a “hold” rating to a “sell” rating in a research note on Monday, March 4th. HC Wainwright lifted their target price on shares of Merus from $48.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Truist Financial began coverage on shares of Merus in a research note on Thursday, March 28th. They issued a “buy” rating and a $69.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 price target on shares of Merus in a research note on Thursday, April 11th. Finally, BMO Capital Markets lifted their price target on shares of Merus from $49.00 to $58.00 and gave the company an “outperform” rating in a research note on Thursday, February 29th. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $56.33.

Merus Price Performance

NASDAQ:MRUS opened at $40.47 on Friday. The firm has a 50-day moving average of $45.11 and a 200-day moving average of $32.97. The company has a market cap of $2.38 billion, a PE ratio of -13.31 and a beta of 1.10. Merus has a one year low of $18.21 and a one year high of $52.03.

Merus (NASDAQ:MRUS) last posted its earnings results on Wednesday, February 28th. The biotechnology company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.38). The business had revenue of $8.94 million for the quarter, compared to the consensus estimate of $10.43 million. Merus had a negative return on equity of 50.61% and a negative net margin of 352.56%. On average, equities research analysts expect that Merus will post -3.29 earnings per share for the current fiscal year.

Merus Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.